Views & Analysis | Perspectives on pharma industry issues

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

R&D

Changing Faces: Pharma and biotech hires, June & July 2026

In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

Market Access

The US biosimilar market: Predictions for 2021

It has been five years since the first biosimilar launched in the United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients

Views & Analysis

Patients as Partners Europe: Are we doing patient centricity...

To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework?

Views & Analysis

Unlocking health data to improve oncology outcomes

As the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial health data and real-world evidence (RWE) environment.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs